Healthcare Resource Utilization and Economic Burden of Prurigo Nodularis in the United States
Patients with PN receiving advanced therapy had higher HCRU and costs versus localized/no therapy. Patients with PN (particularly those receiving advanced therapies) incurred higher all-cause HCRU burden and associated costs than matched controls. Enhanced feature (slides, video, animation) (MP4 12313 KB).
Authors
- Donia Bahloul (ORCID: https://orcid.org/0009-0008-9887-8159)
- Eunice Chang (ORCID: https://orcid.org/0000-0003-0177-6153)
- Ryan B. Thomas (ORCID: https://orcid.org/0000-0002-1141-2073)
- Shawn G. Kwatra (ORCID: https://orcid.org/0000-0003-3736-1515)
- Caleb Paydar (ORCID: https://orcid.org/0000-0003-1636-5947)
- Chao Chen (ORCID: https://orcid.org/0000-0002-4422-1716)
- Ashis Das (ORCID: https://orcid.org/0000-0002-7110-9463)
Institutions
- University of Maryland, Baltimore (US)
- Regeneron (United States) (US)
- Sanofi (France) (FR)
- Partnership for Health Analytic Research (US)
Publication Details
- Journal
- Dermatology and Therapy
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1007/s13555-025-01349-7
- Citations
- 3
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 6.01
Funders
- Sanofi
- Regeneron Pharmaceuticals